-
Views
-
Cite
Cite
Roland W. Sutter, Ali Jaffer M. Suleiman, Pradeep G. Malankar, Firdosi R. Mehta, Mahmud A. Medany, Mohammed Amir M. Arif, Robert W. Linkins, Mark A. Pallansch, Mussalam S. El-Bualy, Susan E. Robertson, Sequential Use of Inactivated Poliovirus Vaccine followed by Oral Poliovirus Vaccine in Oman, The Journal of Infectious Diseases, Volume 175, Issue Supplement_1, February 1997, Pages S235–S240, https://doi.org/10.1093/infdis/175.Supplement_1.S235
- Share Icon Share
Abstract
Seroprevalence and geometric mean titers (GMTs) were compared at 6 and 10 months after vaccination with monovalent type 1 oral poliovirus vaccine (OPV) at 6 months and trivalent OPV at 7 and 9 months. Group 1 had received 4 doses of OPV, group 2 OPV at birth and 3 doses of OPV and inactivated poliovirus vaccine (IPV), and group 3 placebo at birth and 3 doses of IPV. A total of 547 infants completed the study. At 10 months, seroprevalence to poliovirus type 1 was 98%, 99%, and 98% in groups 1, 2, and 3; 100%, 100%, and 98% to poliovirus type 2; and 80%, 96%, and 91% to poliovirus type 3. Differences in seroprevalence among the groups were significant for poliovirus type 3 (P < .001). Between 6 and 10 months, significant increases in seroprevalence and GMTs occurred for poliovirus type 1 but not for types 2 and 3. Two OPV doses following 3 IPV doses did not significantly increase seroprevalence or raise GMTs for poliovirus types 2 and 3; however, significant increases were found for poliovirus type 1, which may have benefitted from monovalent type 1 administration.